IPO for Athenex, Inc.

$11.00 (Est. Date 06/14/2017)

Athenex is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. The firm has generated its clinical product candidates through its orascovery and SRC kinase inhibition research platforms, which are based on its understanding of human absorption biology and novel approaches to inhibiting kinase activity, respectively.

Show More
This information has been gathered from the company's offering prospectus.

IPO Documentation

Loading...

Key IPO Data

ATNX
NASDAQ
$72,000,000
6,000,000
Credit Suisse
This information has been gathered from the company's offering prospectus.

How Does an IPO Work?

Open a Motif Account

Open a brokerage account to get ready for trading.

Participate in an IPO

Review IPO pricing, prospectus, and other documentation.

Place a Conditional Order

Select an investment amount and fund the IPO.

Receive Your IPO Shares

View your allocated shares on account positions page.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. No offer to buy the securities can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to notice of its acceptance given after the effective date.